Beta Drugs logo

Beta Drugs financials and balance sheet

NSE: BETAPharmaceuticals & BiotechnologySmall Cap

Last close ₹1,894.60down ₹76.40 (3.88%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,971.00.

52-week range of traded prices to 23 Oct 2026
₹990.10Low, 25 Feb 2026₹2,807.90High, 12 Aug 2026
Market cap
₹2,107 Cr1,305th largest listed
P/E
39.0
P/B
4.8
Dividend yield
Nonein the last 12 months
ROE
16.4%
ROCE
14.2%
Debt to equity
0.10
Volume, NSE
1,55,58635.7% delivered

9 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Beta Drugs annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹225 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue225
  2. Materials and goods−122
  3. Employee costs−34
  4. Other expenses−40
  5. Operating profit29
  6. Depreciation−9.7
  7. Other income+11
  8. One-off items0.0
  9. Finance costs−12
  10. Profit before tax18
  11. Tax−3.9
  12. Net profit14

What the company owns

  • Plant, investments and other assets₹131 Cr
  • Cash and bank₹118 Cr
  • Receivables₹54 Cr
  • Inventory₹31 Cr

What pays for it: net worth and liabilities

  • Net worth₹150 Cr
  • Borrowings₹130 Cr
  • Owed to suppliers₹44 Cr
  • Other liabilities₹11 Cr

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the year to Mar 2023.Beta Drugs quarterly results

₹ croreMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 15 MayMar 2026Filed 14 May
Revenue from operations51586579125–198220225
41485464100–164194197
Materials and goods bought2830354371–112120122
Employee costs63569–14–34
Other expenses714141520–37–40
Operating profit before depreciation910121525–342729
Operating margin18.7%17.8%18.0%19.3%20.2%–17.0%12.1%12.7%
Materials, % of revenue55.8%52.4%53.3%54.7%56.6%–56.8%–54.3%
Employee costs, % of revenue11.3%5.9%7.6%7.6%7.0%–7.2%–15.1%
Other expenses, % of revenue14.3%23.9%21.2%18.4%16.2%–19.0%–18.0%
Depreciation and amortisation22355–5710
Operating profit after depreciation8891020–291919
Other income00011–2611
Finance costs11110–1512
Profit before one-off items and tax7791020–292518
One-off items00000–0–0
Profit before tax7791020–292118
00236–854
Net profit787714–221514
Other comprehensive income––––––––0
Total comprehensive income––––––––14
Net margin13.4%13.3%10.9%8.8%11.4%–11.1%7.0%6.4%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2025 they do not, so they are left blank.

Balance sheet

Standalone, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2025Filed 15 MayMar 2026Filed 14 MaySep 2026Half yearFiled 22 Oct
129150318
Share capital101011
Reserves119139307
12413021
585464
13013117
Total assets317335398
76117190
240218208
Net debt−1812−77
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021, Mar 2022 and Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2025Filed 15 MayMar 2026Filed 14 MaySep 2026Half yearFiled 22 Oct
13198
333313
0−7−8
Receivables2−5−10
Inventories−6−4−3
Payables542
Other working capital−1−13
Capital spending20293
Free cash flow−7−104
−21−31−75
118−1148
Dividends paid000
Shares bought back–00
Shares issued00159
Net change in cash110−24−20
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021, Mar 2022 and Mar 2024.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2022Mar 2023Mar 2024Mar 2025Filed 15 MayMar 2026Filed 14 May
Earnings per share–––₹15.29₹14.14
Diluted earnings per share–––₹15.29₹14.14
Book value per share–––₹127.83₹147.54
Shareholder yield–––0.0%0.0%
Market cap at the year end (₹ crore)544–1,1861,9241,201

Ratios

Standalone, years to March.Beta Drugs PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 15 MayMar 2026Filed 14 May
Revenue growth–14.8%12.5%21.6%57.1%––11.4%2.4%
Operating profit growth–9.0%14.0%30.3%64.5%––−20.5%7.1%
Net profit growth–14.1%−8.0%−1.7%104.2%––−29.7%−7.1%
Earnings per share growth––––––––−7.5%
–––––––12.0%10.3%
––––––––−1.7 pts
From the net margin––––––––−1.1 pts
From asset turnover––––––––−0.1 pts
From borrowing––––––––−0.5 pts
Return on capital employed–––––––7.6%6.7%
Cash conversion–––––––87.3%133.9%
Interest cover7.510.714.313.047.8–27.54.01.6
Debt to equity–––––––0.960.87
Receivable days–––––––8187
Inventory days–––––––8494
Payable days–––––––124132
Cash conversion cycle, days–––––––4149
Working capital days–––––––6882
Asset turnover–––––––0.700.69
Assets per rupee of net worth–––––––2.452.34
Sales per rupee of plant–––––––4.603.26
Capital spending to depreciation–––––––2.723.02
Plant being built, % of plant in use––––––––0.0%
No balance sheet is on record for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021, Mar 2022 and Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.4%
Cash from operations against operating profit
67.3%
Measure5 years3 years
Revenue growth, yearly rate23.2%–
Profit growth, yearly rate15.5%–
Return on equity, average–11.1%
Return on capital employed, average–7.2%
Operating margin, average15.5%13.9%
Net margin, average9.0%8.2%
Asset turnover, average–0.69
Cash conversion cycle, days, average–45
Interest cover, average20.211.0
Debt to equity, average–0.92

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations19.2
Cash from investing−31.3
Cash from financing−11.4
Capital spending29.2
Dividends paid0.0
Shares bought back0.0
Shares issued for cash0.2
Borrowings raised1.4
Borrowings repaid7.8

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Effective tax ratePublished threshold 17.16 per cent1.05––––––––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
6 Jul 2026Brickwork Ratings India Private Limited (opens in a new tab)Bank Loan RatingsBWR A-Review, OtherStable31.89
6 Jul 2026Brickwork Ratings India Private Limited (opens in a new tab)Bank Loan RatingsBWR A2Review, Other6
20 Jan 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil BBB+Review, Re-affirmPositive5
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.